Supplementary Online Content

Sun M, Lai H, Na F, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. *JAMA Netw Open.* 2023;6(2):e230023. doi:10.1001/jamanetworkopen.2023.0023

eMethods. eResults. eTable 1. Detailed Search Strategy eTable 2. Excluded Studies List eTable 3. Baseline Characteristics of Included Trials eTable 4. Baseline Characteristics of Included Trials eTable 5. Risk of Bias Assessment in Dichotomous Outcomes eTable 6. Risk of Bias Assessment in Continuous Outcomes eTable 7. League Table of All-Cause Mortality in Fixed-effect Model eTable 8. League Table of All-Cause Mortality in Random-effects Model eTable 9. League Table of Rate of RSV Infection in Fixed-effect Model eTable 10. League Table of Rate of RSV Infection in Random-effects Model eTable 11. League Table of RSV-Related Hospitalization in Fixed-effect Model eTable 12. League Table of RSV-Related Hospitalization in Random-effects Model eTable 13. League Table of Rate of ICU Admission in Fixed-effect Model eTable 14. League Table of Rate of ICU Admission in Random-effects Model eTable 15. League Table of Rate of Mechanical Ventilation Use in Fixed-effect Model eTable 16. League Table of Rate of Mechanical Ventilation Use in Random-effects Model eTable 17. League Table of Drug-related Adverse Events in Fixed-effect Model eTable 18. League Table of Drug-related Adverse Events in Random-effects Model eTable 19. League Table of Rate of Supplemental Oxygen Use in Fixed-effect Model eTable 20. League Table of Rate of Supplemental Oxygen Use in Random-effects Model eTable 21. Cumulative Ranking of Interventions for Different Outcomes eTable 22. Details of GRADE Assessment in All-cause Mortality eTable 23. Details of GRADE Assessment in RSV-related Hospitalization eTable 24. Details of GRADE Assessment in Rate of RSV Infection **eTable 25.** Details of GRADE Assessment in Drug-related Adverse Events eTable 26. Details of GRADE Assessment in Supplemental Oxygen Use eTable 27. Details of GRADE Assessment in Rate of Mechanical Ventilation Use eTable 28. Details of GRADE Assessment in Rate of ICU Admission eTable 29. Details of GRADE Assessment in Drug-related Serious Adverse Events eTable 30. Bayesian League Table of Rate of RSV Infection in Random-effects Model eTable 31. Bayesian League Table of Rate of RSV Infection in Fixed-effect Model eTable 32. Bayesian League Table of All-cause Mortality in Random-effects Model eTable 33. Bayesian League Table of All-cause Mortality in Fixed-effect Model eTable 34. Bayesian League Table of RSV-related Hospitalization in Random-effects Model eTable 35. Bayesian League Table of RSV-related Hospitalization in Fixed-effect Model

- Model **eTable 37.** Bayesian League Table of Rate of Supplemental Oxygen Use in Fixed-effect

 Model
- **eTable 38.** Bayesian League Table of Rate of Mechanical Ventilation Use in Random-effects Model

eTable 36. Bayesian League Table of Rate of Supplemental Oxygen Use in Random-effects

eTable 39. Bayesian League Table of Rate of Mechanical Ventilation Use in Fixed-effect Model

- eTable 40. Bayesian League Table of Rate of ICU Admission in Random-effects Model
- eTable 41. Bayesian League Table of Rate of ICU Admission in Fixed-effect Model
- **eTable 42.** Bayesian League Table of Drug-related Adverse Events in Random-effects Model
- eTable 43. Bayesian League Table of Drug-related Adverse Events in Fixed-effect Model
- **eTable 44.** Bayesian League Table of Drug-related Serious Adverse Events in Random-effects Model
- **eTable 45.** Bayesian League Table of Drug-related Serious Adverse Events in Fixed-effect Model
- eTable 46. Details of Continuous Outcomes
- **eFigure 1.** Risk of Bias Assessment
- eFigure 2. Network Plot of Rate of RSV Infection
- eFigure 3. Network Plot of All-cause Mortality
- eFigure 4. Network Plot of RSV-related Hospitalization
- eFigure 5. Network Plot of Supplemental Oxygen Use
- eFigure 6. Network Plot of Rate of Mechanical Ventilation Use
- eFigure 7. Network Plot of Rate of ICU Admission
- eFigure 8. Network Plot of Drug-related Adverse Events
- eFigure 9. Network Plot of Drug-related Serious Adverse Events
- eFigure 10. Results of Motavizumab Compared With Placebo in All-cause Mortality
- eFigure 11. Results of Nirsevimab Compared With Placebo in All-cause Mortality
- eFigure 12. Results of Palivizumab Compared With Placebo in All-cause Mortality
- eFigure 13. Results of Suptavumab Compared With Placebo in All-cause Mortality
- eFigure 14. Results of Motavizumab Compared With Palivizumab in All-cause Mortality
- **eFigure 15.** Results of Motavizumab in Combination With Palivizumab Compared With Motavizumab in All-cause Mortality
- **eFigure 16.** Results of Nirsevimab Compared With Placebo in Drug-related Adverse Events
- **eFigure 17.** Results of Palivizumab Compared With Placebo in Drug-related Adverse Events
- **eFigure 18.** Results of Suptavumab Compared With Placebo in Drug-related Adverse Events
- **eFigure 19.** Results of Motavizumab Compared With Palivizumab in Drug-related Adverse Events
- **eFigure 20.** Results of Motavizumab in Combination With Palivizumab Compared With Motavizumab in Drug-related Adverse Events
- **eFigure 21.** Results of Motavizumab Compared With Placebo in Drug-related Serious Adverse Events
- **eFigure 22.** Results of Nirsevimab Compared With Placebo in Drug-related Serious Adverse Events
- **eFigure 23.** Results of Palivizumab Compared With Placebo in Drug-related Serious Adverse Events
- **eFigure 24.** Results of Motavizumab Compared With Palivizumab in Drug-related Serious Adverse Events
- **eFigure 25.** Results of Motavizumab in Combination With Palivizumab Compared With Motavizumab in Drug-related Serious Adverse Events
- **eFigure 26.** Results of Nirsevimab Compared With Placebo in RSV-related Hospitalization
- eFigure 27. Results of Palivizumab Compared With Placebo in RSV-related Hospitalization
- efigure 28. Results of Suptavumab Compared With Placebo in RSV-related Hospitalization
- **eFigure 29.** Results of Motavizumab Compared With Palivizumab in RSV-related Hospitalization
- eFigure 30. Results of Motavizumab Compared With Placebo in RSV Infection
- eFigure 31. Results of Nirsevimab Compared With Placebo in RSV Infection
- eFigure 32. Results of Palivizumab Compared With Placebo in RSV Infection
- eFigure 33. Results of Suptavumab Compared With Placebo in RSV Infection
- eFigure 34. Results of Motavizumab Compared With Placebo in Supplemental Oxygen Use
- eFigure 35. Results of Nirsevimab Compared With Placebo in Supplemental Oxygen Use

```
eFigure 36. Results of Motavizumab Compared With Palivizumab in Supplemental Oxygen Use
```

- eFigure 37. Results of Motavizumab Compared With Placebo in Mechanical Ventilation Use
- eFigure 38. Results of Nirsevimab Compared With Placebo in Mechanical Ventilation Use
- eFigure 39. Results of Palivizumab Compared With Placebo in Mechanical Ventilation Use
- **eFigure 40.** Results of Motavizumab Compared With Palivizumab in Mechanical Ventilation Use
- eFigure 41. Results of Motavizumab Compared With Placebo in ICU Admission
- eFigure 42. Results of Nirsevimab Compared With Placebo in ICU Admission
- eFigure 43. Results of Palivizumab Compared With Placebo in ICU Admission
- eFigure 44. Results of Motavizumab Compared With Palivizumab in ICU Admission
- eFigure 45. Funnel Plot of All-cause Mortality
- eFigure 46. Node-split Plot of All-cause Mortality in Fixed-effect Model
- eFigure 47. Node-split Plot of All-cause Mortality in Random-effects Model
- eFigure 48. Node-split Plot of Drug-related Adverse Events in Fixed-effect Model
- eFigure 49. Node-split Plot of Drug-related Adverse Events in Random-effects Model
- eFigure 50. Node-split Plot of Rate of ICU Admission in Fixed-effect Model
- eFigure 51. Node-split Plot of Rate of ICU Admission in Random-effects Model
- eFigure 52. Node-split Plot of Rate of Mechanical Ventilation Use in Fixed-effect Model
- eFigure 53. Node-split Plot of Rate of Mechanical Ventilation Use in Random-effects Model
- eFigure 54. Node-split Plot of Rate of RSV Infection in Fixed-effect Model
- eFigure 55. Node-split Plot of Rate of RSV Infection in Random-effects Model
- eFigure 56. Node-split Plot of Rate of Supplemental Oxygen Use in Fixed-effect Model
- eFigure 57. Node-split Plot of Rate of Supplemental Oxygen Use in Random-effects Model
- eFigure 58. Node-split Plot of RSV-related Hospitalization in Fixed-effect Model
- eFigure 59. Node-split Plot of RSV-related Hospitalization in Random-effects Model
- **eFigure 60.** Contribute Plot of All-cause Mortality
- eFigure 61. Contribute Plot of Rate of RSV Infection
- eFigure 62. Contribute Plot of RSV-related Hospitalization
- eFigure 63. Contribute Plot of Rate of ICU Admission
- eFigure 64. Contribute Plot of Rate of Supplemental Oxygen Use
- eFigure 65. Contribute Plot of Rate of Mechanical Ventilation Use
- **eFigure 66.** Contribute Plot of Drug-related Adverse Events
- eFigure 67. Subgroup Analysis of Rate of RSV Infection
- eFigure 68. Subgroup Analysis of RSV-related Hospitalization
- **eFigure 69.** Meta-regression of Age in RSV-related Hospitalization
- eFigure 70. Meta-regression of Gender in RSV-related Hospitalization
- eFigure 71. Meta-regression of Publication Year in RSV-related Hospitalization
- **eFigure 72.** Comparison of Different Monoclonal Antibodies on Efficacy and Safety Outcomes

This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods

Statistical Analysis

Network meta-analysis: We conducted a random-effect model network meta-analysis using a consistency model with "netmeta V1.0-1" package under a frequentist framework in R 1.3.1093 software. Frequentist results were shown in league tables. A league table is a square matrix showing all pairwise comparisons in a network meta-analysis. Typically, both treatment estimates and confidence intervals are shown. The netsplit function was used to assess the inconsistency between direct and indirect estimates and obtain indirect effect estimates. Network estimates that have indirect and direct evidence, these estimates are split into three components. The network estimate, indirect estimate and direct estimate are inspected for consistency. Consistency is assessed mainly by inspection of the point estimate and the confidence intervals. P-scores were used to rank each intervention with the interpretation of the mean extent of certainty that one intervention was better than the other. We used contribute plots to presents the contribution of every interventions. This fuction generates the contribution of direct comparisons to every network treatment comparison. The contribution matrix shows how much each direct treatment effect contributes to each treatment effect estimate from network meta-analysis. The output is a matrix where rows represent network treatment effects and columns represent the contribution of direct treatment effects.

<u>Pairwise meta-analyses:</u> Pairwise meta-analyses were performed using RevMan 5.4.1, and the data were synthesized with a random-effects model to obtain direct effect estimates for each pairwise comparison.

Subgroup analysis, meta-regression, and sensitivity analysis: We conducted the subgroup analysis in direct comparisons for a priori specified variables including health status (healthy vs unhealthy, a predefined hypothesis of larger effect in unhealthy population; unhealthy was defined as participants reported having high-risk factors at baseline). We also performed meta-regression in gestational age, and ratio of male and female. Meta-regression is similar to simple regression, where the outcome of interest is predicted on the basis of one or more explanatory variables. Besides, we performed sensitivity analyses to observe the robustness of results by repeating the analyses using a bayesian hierarchical model, and using both fixed-effects model and random-effects model.

eResults

Network meta-analysis: Frequentist results were shown in league tables (appendix table S7-20). P-scores were used to rank each intervention with the interpretation of the mean extent of certainty that one intervention was better than the other (appendix table S21). The network plots were shown in appendix figure S2-9. The line width is proportional to the number of studies comparing each pair of interventions, and the size of each node is proportional to the number of participants (sample size). The node-split plots were shown in appendix figure S48-61. The contribute plots were shown in appendix figure S62-68, the matrix showed how much each direct treatment effect contributes to each treatment effect estimate from network meta-analysis.

<u>Pairwise meta-analyses:</u> Results of pairwise meta-analyses were shown in forest plots (appendix figure S10-46). Funnel plot of all-cause mortality was presented in appendix figure S47, showing that there may be no publication bias.

<u>Subgroup analysis, meta-regression, and sensitivity analysis:</u> Bayesian results were shown in league tables as sensitivity analyses (appendix table S31-46).

Appendix table S1: detailed search strategy

Database: PubMed <Mar 13, 2022>

Search Strategy:

#	Searches	Results
1	"Palivizumab" [Mesh]	825
2	((MEDI 493[Title/Abstract]) OR (MEDI-493[Title/Abstract]) OR	9
	(MEDI493[Title/Abstract]) OR (Monoclonal Antibody MEDI-493[Title/Abstract]) OR	
	(Monoclonal Antibody MEDI 493[Title/Abstract]) OR (Monoclonal Antibody	
	MEDI493[Title/Abstract]))	
3	"Synagis" [Title/Abstract]	107
4	or/1-3	864
5	Motavizumab[Title/Abstract]	51
6	Nirsevimab[Title/Abstract]	14
7	MEDI8897[Title/Abstract]	7
8	Monoclonal antibod*[Title/Abstract]	197,940
9	Antibody, Monoclonal[Title/Abstract]	112
10	"Antibodies, Monoclonal"[Mesh]	261,297
11	or/4-10	345,203
12	"Respiratory Syncytial Viruses"[Mesh]	9,813
13	((Respiratory Syncytial Virus[Title/Abstract]) OR (Syncytial Virus,	15,694
	Respiratory[Title/Abstract]) OR (Syncytial Viruses, Respiratory[Title/Abstract]) OR	
	(Virus, Respiratory Syncytial[Title/Abstract]) OR (Viruses, Respiratory	
	Syncytia[Title/Abstract]) OR (Respiratory Syncytial Virus, Human) OR (Human	
	respiratory syncytial virus))	
14	#12 OR #13	16,669
15	"Respiratory Tract Infections"[Mesh]	518,149
16	((Infection, Respiratory Tract[Title/Abstract]) OR (Respiratory Tract	28,593
	Infection[Title/Abstract]) OR (Infections, Respiratory[Title/Abstract]) OR (Infections,	
	Respiratory Tract[Title/Abstract]) OR (Respiratory Infections[Title/Abstract]))	
17	#15 OR #16	53,1434
18	"Pneumonia"[Mesh]	242,236
19	"Bronchiolitis"[Mesh]	9,276
20	#14 OR #17 OR #18 OR #19	543,979
21	#11 and #20	7,413
22	"clinical trial" [Publication Type]	931,808
23	"Clinical Trials as Topic"[Mesh]	371,437
24	"Double-Blind Method"[Mesh]	170,548
25	(randomized[TIAB] AND (trial[TIAB] OR trials[tiab]))	411,238

26	((single[TIAB] OR double[TIAB] OR doubled[TIAB] OR triple[TIAB] OR tripled[TIAB]	210,876		
	OR treble[TIAB] OR treble[TIAB]) AND (blind*[TIAB] OR mask*[TIAB]))			
27	or/22-26	1,408,659		
28	#21 and #27	890		

Database: Embase <Mar 13, 2022>

Search Strategy:

#	Searches	Results
1	'palivizumab'/exp	3,293
2	palivizumab:ti,ab,kw	1,544
3	synagis:ti,ab,kw	179
4	'medi493'ti,ab,kw	12
5	'motavizumab'/exp	304
6	motavizumab:ti,ab,kw	69
7	'nirsevimab'/exp	71
8	nirsevimab:ti,ab,kw	20
9	MEDI8897:ti,ab,kw	15
10	'monoclonal antibody'/exp	673,595
11	or/1-10	673,737
12	'respiratory syncytial virus infection'/exp	6,669
13	'respiratory syncytial virus' OR rsv	32,136
14	'bronchiolitis'/exp	24,500
15	bronchiolit*ti,ab,kw	19,154
16	'pneumonia'/exp	369,534
17	pneumon*:ti,ab,kw OR bronchopneumon*:ti,ab,kw OR pleuropneumon*:ti,ab,kw	320,840
18	'respiratory tract infection'/exp	517,513
19	'lower respiratory infection*':ti,ab,kw	2,305
20	'lower respiratory tract infection*':ti,ab,kw OR lrti:ti,ab,kw	11,138
21	'pneumovirus'/exp OR 'human respiratory syncytial virus'/exp	20,047
22	or/12-21	884,506
23	#11 and #22	44,911
24	rct:ti,ab,kw OR 'randomized controlled trial':ti,ab,kw	163,460
25	'randomized controlled trial'/exp	702,816
26	#24 or #25	756,536
27	#23 and 26	3,662

Database: CENTRAL <Mar 13, 2022>

Search Strategy:

#	Searches	Results
1	MeSH descriptor: [Palivizumab] explode all trees	49
2	(palivizumab):ti,ab,kw	146
3	(synagis):ti,ab,kw	33
4	(medi493);ti,ab,kw	0
5	(motavizumab):ti,ab,kw	23

6	(nirsevimab):ti,ab,kw	6
7	(MEDI8897):ti,ab,kw	14
8	MeSH descriptor: [Antibodies, Monoclonal] explode all trees	15,035
9	or/1-8	15,147
10	MeSH descriptor: [Respiratory Syncytial Virus] explode all trees	177
11	MeSH descriptor: [Respiratory Syncytial Virus Infections] explode all trees	330
12	((respiratory syncytial virus* or rsv)):ti,ab,kw	1290
13	MeSH descriptor: [Respiratory Syncytial Virus, Human] explode all trees	69
14	MeSH descriptor: [Bronchiolitis] in all MeSH products	398
15	(bronchiolit*):ti,ab,kw	1,536
16	((pneumon* or bronchopneumon* or pleuropneumon*)):ti,ab,kw	21,846
17	MeSH descriptor: [Respiratory Tract Infections] explode all trees	16,984
18	((lower respiratory infection*))ti,ab,kw	4,409
19	((lower respiratory tract infection* or lrti)):ti,ab,kw	3,420
20	or/10-19	38,085
21	#9 and #20	765

Database: ClinicalTrials.gov <Mar 13, 2022>

#	Searches	Results
1	Intervention: palivizumab OR synagis OR med493 OR motavizumab OR nirsevimab OR	43
	MEDI8897	

Appendix table S2: Excluded studies list

Author, Year	Population	Intervention	Outcome	Study design	Exclude reasons
Ramilo O, 2014	healthy infants	motavizumab	Clinical outcomes data collected included the duration of hospitalization, the need for supplemental oxygen and mechanical ventilation and admission to and length of stay in the intensive care unit (ICU). The incidence of ≥ 1 or ≥ 3 medically attended wheezing episodes	RCT	ineligible population
Meissner HC, 1999	preterm infants with or without bronchopulmonary dysplasia (BPD)	SB 209763	laboratory tests, Safety parameters, RSV disease symptoms, Pharmacokinetic parameters	RCT	unable to extract data
Malley R, 1998	RSV infection	palivizumab	serum concentration	RCT	ineligible population
Mori M, 2014	children ≤24 months	palivizumab	rate of RSV-associated hospitalizations occurring, Blood samples, Adverse events	NRCT	wrong study designs
SÁEZ-LLORENS X, 1998	preterm infants with or without bronchopulmonary dysplasia (BPD)	palivizumab	Adverse events, laboratory tests, Pharmacokinetic and immunogenicity assessments	NRCT	wrong study designs
Groothuis JR, 2003	preterm infants	palivizumab	need for hospitalization and hospital course, safety	NRCT	wrong study designs
Brunv, 2000	preterm infants	palivizumab	_	NRCT	wrong study designs
Alansari K, 2019	Infants with a confirmed diagnosis of RSV bronchiolitis	palivizumab	The primary efficacy outcome was readmission to either the infirmary- observation unit, hospital, or PICU during the 3 weeks after discharge. Final secondary outcomes were time to medical readiness for discharge on the initial admission, revisit (but not requiring admission) to any medical facility for the same illness in the 3- week follow-up period, and need for transfer to the PICU during the initial admission	RCT	ineligible population
Alyamovskaya, 2012	50–74 years old participants	long-acting beta-2- agonists	The forced expiratory volume in 1 s (FEV1), Skin blood perfusion changes	RCT	ineligible population
Lagos R, 2009	healthy children aged <2 years (gestational age >36 weeks)	motavizumab	lower respiratory disease scores, the durations of hospitalization, supplemental oxygen use during hospitalization, in- tensive care unit stay, and mechanical ventilation were also recorded. Adverse events (AEs) and serious AEs were monitored through study day 30	RCT	ineligible population
Null D, 2005	Children at 6 selected centers who had participated in IMpact-	palivizumab	Adverse events, palivizumab concentrations and anti-palivizumab reactivity	NRCT	wrong study designs

^{© 2023} Sun M et al. JAMA Network Open.

	RSV during the 1996–1997 winter season				
Sa'ez-Llorens X, 2004	children ≤24 months	palivizumab	RSV hospitalization and for 30 days after study drug administration for safety, determination of drug serum concentration and clinical outcome	RCT	ineligible population
Domachowske J, 2022	preterm infants with heart or lung disease	nirsevimab	Data on adverse events that occurred during treatment and adverse events of special interest were collected through day 361. Pharma cokinetics and antidrug antibody levels were assessed (see Section S3)	NRCT	wrong study designs
Marchac, 2006		palivizumab		NRCT	wrong study designs
Man WH, 2020	healthy preterm infants; Infants were younger than 6 months of age at the start of the RSV season	palivizumab	primary outcome was to assess the effect of palivizumab during infancy on the respiratory microbiota composition at age 1 year and 6 years; secondary outcomes were assessment of the effect of proven RSV infection in the first year of life on the respiratory microbiota composition at age 1 years and 6 years	RCT	unable to extract data
Makari D, 2014	preterm infants with chronic lung disease	palivizumab liquid	adverse events, Antidrug Antibodies	RCT	ineligible controls
Blanken M, 2012	Healthy preterm infants	palivizumab	The primary endpoint of the study was the number of wheezing days during the first year of life	RCT	unable to extract data

Appendix table S3: Baseline characteristics of included trials

First aut hor, Yea r	Registe r numbe r	Journal	Country	Weight (mean±S D)	As ia n (%)	W hi te (%	Bl a c k (%	Hispani c (%)	American Indian or Alaska Native (%)	Native Hawaiian or other Pacific Islander (%)	Ot h e r (%)	Multip le catego ries (%)
Griffin, 2020	NCT02 8 78330	N Engl J Med	Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czech Republic, Estonia, Finland, France, Hungary, Italy, Latvia, Lithuania, New Zealand, Poland, South Africa, Spain, Sweden, Turkey, United Kingdom, United States	4.57±1 .93	1.03	72 .1 8	1 7	N R	0.07	0.76	7. 16	1.17
O'Bri en, 2015	NCT00 1 21108	Lancet Infect Dis	United States	5.16±1 .79	NA	N A	N A	N R	98.78	NA	1. 22	NA
Subrama ni an, 1998	NR	Pediat ric Infecti ous Diseas e Journal	NR	4.67±0 .72	NR	N R	N R	N R	NR	NR	N R	NR
Hammitt , 2022	NCT03 9 79313	Northern (69%), Southern (31%): Austria, Belgium, Bulgaria, Canada, Estonia, Finland, France, Germany, Israel, Japan, Lativa, Lithuania, Poland, Republic of Korea, Russia, South Africa, Spain, Sweden, United		NR	3.6	53 .5	2 8	N R	5.6	0.7		8.1

	NCT002		Austria, Belgium, Bulgaria, Canada, Czech									
Feltes,	40890,	Pediatric	Republic, Denmark, France, Germany, Hungary,	6.70.061	1.46	06.56	2.40	2.56	N.D.	NE	4.04	N.D.
2011	NCT005	Research	Israel, Lebanon, Poland, Russia, Spain, Sweden,	6.72±2.61	1.46	86.56	3.48	3.56	NR	NR	4.94	NR
	38785		United Kingdom, United									
			States									
			United States, Canada, Austria, Czech Republic,									
Carbonell-	NCT001		Denmark, France, Germany, Greece, Hungary,									
Estrany,	29766	Pediatrics	Italy, Poland, Spain, Sweden, United Kingdom,	4.45±1.99	1.28	78.57	7.85	8.58	NR	NR	3.69	NR
2010	29700		Argentina, Australia, Brazil, Bulgaria, Chile,									
			Iceland, Israel, New Zealand, Russia,									
			Turkey									
Feltes,	NR	Journal of	United States, Canada, Poland, the United Kingdom,	6.05±0.1	NR	70.86	8.78	11.11	NR	NR	9.25	NR
2003	7.11	Pediatrics	Germany, Sweden, France	0100_011	1,11	, 0.00	0.70					<u> </u>
IMpact- RSV, 1998	NR	Pediatrics	United States, the United Kingdom, Canada	4.83±0.1	2.2	58.06	23.7	10.92	NR	NR	5.13	NR
		Clin Infect										
Simões,	NCT023	Dis		4.47±1.54	0.7	86.86	8.79	NR	0.17	0.17	2.35	
2021	25791	Clin Infect	18 countries									NR
		Dis.										
	ISRCTN											
Scheltema,	7364171	Lancet	Netherlands	2.29	NR	NR	NR	NR	NR	NR	NR	NR
2018	0	Respir										
		Med										
		Pediatric										
Domachow	NCT022	Infectious	United States, South Africa, Chile	6.82±1.9	1.4	11.3	57.7	NR	1.4	NR	25.4	2.8
ske, 2018	90340	Disease	Since States, South Finea, Since	0.02_1.7	1.7	11.3	5/./	NK	1.4		25.4	2.0
		Journal										
Tavsu,	NR	Am J	NR	1.36±0.26	NR	NR	NR	NR	NIR	NR	NIR	NR
2014	1417	Perinatol.	IM	1.30±0.26	INIX	1414	1417	IVIX	NR	NR	NR	1417

Fernández,	NCT003	BMC	Chile, New Zealand, Australia	4.6±1.8	NR	27.3	NR	63.8	NR	NID	99	NR
2010	16264	Pediatrics	Cinic, New Zealand, Australia	4.0±1.0	NIX	27.5	INIX	03.6	IVIX	IVIX	8.8	TVIX

Appendix table S4: Baseline characteristics of included trials

First autho r, Year	≥1 smoker in househol d	Overal l smoke exposu re	Househol d crowding ,>5 individua ls	Bronchop ul monary dysplasia (BPD) (%)	Congenit al heart disease (CHD) (%)	Chroni c lung disease (CLD) (%)	Timpoint of trial (before/during/a fte r RSV season)	Any atop y (%)	Asthma/ W heezing (%)	Eczem a (%)	Ha y feve r (%)	Fun ding	
Griffin, 2020	NR	NR	NR	NA	NA	NA	before	NR	NR	NR	NR	MedImmune/AstraZeneca and Sanofi Pasteur MedImmune	
O'Brien, 2015	22.57	67.94	77.76	NA	NA	NA	during	20.73	18.85	4.33	8.6		
Subramani an, 1998	NR	NR	NR	83.87	NR	NR	during	NR	NR	NR	NR	NR	
Hammitt,	NR	NR	NR	NA	NA	NA	before	NR	NR	NR	NR	MedImmune/ AstraZeneca and Sanofi	
Blanken, 2013	16.08/27.74/ 38.93	NR	NR	NA	NA	NA	during	36.6/35 .66	10.72/11.19	18.18/13. 05	21.68/2 2.38	Abbott Laboratories and by the Netherlands Organization for Health Research and Development	
Feltes, 2011	38.14	NR	NR	NA	100	NA	during	38.38	NR	NR	NR	MedImmune	
Carbonell - Estrany, 2010	32.99	NR	NR	NR	NR	21.78	during	44.6	27.99	16.46	20.38	NR	
Feltes, 2003	33.72	NR	NR	NA	100	NA	during	NR	28.21	NR	NR	NR	

IMpact- RSV, 1998	35.15	NR	NR	50.73	NA	NA	during	NR	35.82	16.44	28.96	NR
Simões, 2021	NR	NR	NR	NA	NA	NA	over 3 RSV seasons	NR	NR	NR	NR	Regeneron Pharmaceuticals
Scheltema, 2018	16.08/27.74/ 38.93	NR	NR	NA	NA	NA	during	36.6/35 .66	10.72/11.19	18.18/13. 05	21.68/2 2.38	AbbVie
Domachows ke, 2018	NR	NR	NR	NA	NA	NA	NR	NR	NR	NR	NR	MedImmune
Tavsu, 2014	NR	NR	NR	NA	NA	NA	during	NR	NR	NR	NR	NR
Fernández, 2010	NR	NR	NR	NR	NR	15.8	during	NR	NR	NR	NR	MedImmune

Appendix table S5: risk of bias assessment in dichotomous outcomes

Study	Randomization process generated	Deviations from the intended intervention	Missing data	Measurement of the outcome	Selection of the reported results	Overall
Griffin MP, 2020	Low	Low	Low	Low	Low	Low
O'Brien KL, 2015	Low	Low	Low	Low	Low	Low
Subramanian KN, 1998	Low	Low	Low	Low	Low	Low
Hammitt LL, 2022	Low	Low	Low	Low	Low	Low
Blanken MO, 2013	Low	Low	Low	Low	Low	Low
FELTES TF, 2011	Low	Low	Low	Low	Low	Low
Carbonell-Estrany X, 2010	Low	Low	Low	Low	Low	Low
FELTES TF, 2003	Low	Low	Low	Low	Low	Low
IMpact-RSV, 1998	Low	Low	Low	Low	Low	Low
Simões EAF, 2021	Someconcerns	Low	Low	Low	Low	Someconcerns
Scheltema NM, 2018	Low	Low	Low	Low	Low	Low
Domachowske JB, 2018	Someconcerns	Low	Low	Low	Low	Someconcerns
Tavsu I, 2014	Someconcerns	Someconcerns	Low	Low	Low	Someconcerns
Fernández P, 2010	Low	Low	Low	Low	Low	Someconcerns*

^{*} MedImmune was involved in study design, and analysis and interpretation of data.

Appendix table S6: risk of bias assessment in continuous outcomes

Study	Randomization process generated	Deviations from the intended intervention	Missing data	Measurement of the outcome	Selection of the reported results	Overall
Griffin MP, 2020	Low	Low	Low	Low	Low	Low
O'Brien KL, 2015	Low	Low	Low	Low	Someconcerns	Someconcerns
Subramanian KN, 1998	Low	Low	Low	Low	Low	Low
Hammitt LL, 2022	Low	Low	Low	Low	Low	Low
Blanken MO, 2013	Low	Low	Low	Low	Low	Low
FELTES TF, 2011	Low	Low	Low	Low	Low	Low
Carbonell-Estrany X, 2010	Low	Low	Low	Low	Someconcerns	Someconcerns
FELTES TF, 2003	Low	Low	Low	Low	Someconcerns	Someconcerns
IMpact-RSV, 1998	Low	Low	Low	Low	Low	Low
Simões EAF, 2021	Someconcerns	Low	Low	Low	Low	Someconcerns
Scheltema NM, 2018	Low	Low	Low	Low	Low	Low
Domachowske JB, 2018	Someconcerns	Low	Low	Low	Low	Someconcerns
Tavsu I, 2014	Someconcerns	Someconcerns	Low	Low	Low	Someconcerns
Fernández P, 2010	Low	Low	Low	Low	Low	Someconcerns*

st MedImmune was involved in study design, and analysis and interpretation of data.

Appendix table S7-S20: league tables of outcomes in fixed and random models

Outcomes were reported as odds ratio (95% credible interval). All tables list the treatments in alphabetical order. The estimate is in the cell in common between the column-defining intervention and the row-defining intervention. The league table contains the network estimates in the lower triangle and the direct treatment estimates from pairwise comparisons in the upper triangle. The blanks indicate that there is no comparison group for this outcome.

*Included studies for each outcome assessment:

Author, year	Intervention vs	all-cause	rate of	RSV-related	rate of ICU	rate of	drug-related	rate of
	comparison	mortality	RSV	hospitalization	admission	mechanical	adverse events	supplemental
			infection			ventilation use		oxygen use
Griffin, 2020	Nirsevimab vs	$\sqrt{}$	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	$\sqrt{}$
	placebo							
O'Brien, 2015	Motavizumab	\checkmark	\checkmark		√	\checkmark		\checkmark
	vs placebo							
Subramanian,	Palivizumab vs	√	√	√			√	
1998	placebo							
Hammitt, 2022	Nirsevimab vs	\checkmark	$\sqrt{}$	√			$\sqrt{}$	
	placebo							
Blanken, 2013	Palivizumab vs		$\sqrt{}$	√				
	placebo							
Feltes, 2011	Motavizumab	\checkmark					$\sqrt{}$	
	vs Palivizumab							
Carbonell-	Motavizumab			√	√	\checkmark	\checkmark	√
Estrany, 2010	vs Palivizumab							
Feltes, 2003	Palivizumab vs	\checkmark		\checkmark	√	\checkmark	\checkmark	
	placebo							
IMpact-RSV,	Palivizumab vs	\checkmark		\checkmark				
1998	placebo							
Simões, 2021	Suptavumab vs	\checkmark	\checkmark	\checkmark			$\sqrt{}$	
	placebo							
Scheltema,	Palivizumab vs		\checkmark					
2018	placebo							
Domachowske,	Nirsevimab vs	√					√	
2018	placebo							
Tavsu, 2014	Palivizumab vs		$\sqrt{}$	√				
	placebo							
Fernández,	M+P vs	√				_	√	
2010	Motavizumab							

Appendix table S7: league table of all-cause mortality in fixed effects model

M+P	1.12 (0.10 - 12.54)			
1.12 (0.10 - 12.54)	Motavizumab	·	0.89 (0.36 - 2.20)	1.00 (0.18 - 5.48)
2.43 (0.11 - 55.88)	2.16 (0.29 - 16.03)	Nirsevimab		0.33 (0.05 - 1.97)
1.10 (0.09 - 14.04)	0.98 (0.44 - 2.20)	0.45 (0.07 - 2.93)	Palivizumab	0.70 (0.41 - 1.19)
0.80 (0.06 - 10.46)	0.71 (0.29 - 1.74)	0.33 (0.05 - 1.97)	0.72 (0.43 - 1.21)	Placebo

Appendix table S8: league table of all-cause mortality in random effects model

M+P	1.12 (0.10 - 12.54)	·		·
1.12 (0.10 - 12.54)	Motavizumab	·	0.89 (0.36 - 2.20)	1.00 (0.18 - 5.48)
2.43 (0.11 - 55.88)	2.16 (0.29 - 16.03)	Nirsevimab		0.33 (0.05 - 1.97)
1.10 (0.09 - 14.04)	0.98 (0.44 - 2.20)	0.45 (0.07 - 2.93)	Palivizumab	0.70 (0.41 - 1.19)
0.80 (0.06 - 10.46)	0.71 (0.29 - 1.74)	0.33 (0.05 - 1.97)	0.72 (0.43 - 1.21)	Placebo

Appendix table S9: league table of rate of RSV infection in fixed effects model

Motavizumab			0.17	
Wotavizumao		•	(0.12 - 0.23)	
0.68	Nirsevimab		0.24	
(0.41 - 1.14)	Niiseviinab	•	(0.16 - 0.37)	•
0.52	0.77	5	0.32	
(0.32 - 0.86)	(0.44 - 1.35)	Palivizumab	(0.22 - 0.47)	
0.17	0.24	0.32	P1 1	0.94
(0.12 - 0.23)	(0.16 - 0.37)	(0.22 - 0.47)	Placebo	(0.65 - 1.36)
0.16	0.23	0.30	0.94	Suptavumab
(0.10 - 0.25)	(0.13 - 0.40)	(0.18 - 0.51)	(0.65 - 1.36)	Suptavulliao

Appendix table S10: league table of rate of RSV infection in random effects model

Motavizumab			0.17 (0.12 - 0.23)	
0.68 (0.41 - 1.14)	Nirsevimab		0.24 (0.16 - 0.37)	
0.52	0.77	Palivizumab	0.32	
(0.32 - 0.86)	(0.44 - 1.35)	Panvizumao	(0.22 - 0.47)	•
0.17	0.24	0.32	Placebo	0.94
(0.12 - 0.23)	(0.16 - 0.37)	(0.22 - 0.47)	Praceoo	(0.65 - 1.36)
0.16	0.23	0.30	0.94	Contoursh
(0.10 - 0.25)	(0.13 - 0.40)	(0.18 - 0.51)	(0.65 - 1.36)	Suptavumab

Appendix table S11: league table of RSV-related hospitalization in fixed effects model

Motavizumab		0.73		
Wiotavizumao	·	(0.50 - 1.08)	·	•
1.34	N		0.25	
(0.60 - 3.01)	Nirsevimab		(0.13 - 0.47)	·
0.73	0.55	D.F	0.45	
(0.50 - 1.08)	(0.27 - 1.12)	Palivizumab	(0.34 - 0.60)	•
0.33	0.25	0.45	Placebo	1.00
(0.20 - 0.53)	(0.13 - 0.47)	(0.34 - 0.60)	Piacedo	(0.52 - 1.92)
0.33	0.25	0.45	1.00	G 1
(0.15 - 0.74)	(0.10 - 0.62)	(0.22 - 0.92)	(0.52 - 1.92)	Suptavumab

${\bf Appendix\ table\ S12: league\ table\ of\ RSV-related\ hospitalization\ in\ random\ effects\ model}$

Motavizumab		0.73		
Wiotavizumao	•	(0.50 - 1.08)	•	•
1.34	Nirsevimab		0.25	
(0.60 - 3.01)	Nirsevimao		(0.13 - 0.47)	·
0.73	0.55	D.F. :	0.45	
(0.50 - 1.08)	(0.27 - 1.12)	Palivizumab	(0.34 - 0.60)	·
0.33	0.25	0.45		1.00
(0.20 - 0.53)	(0.13 - 0.47)	(0.34 - 0.60)	Placebo	(0.52 - 1.92)
0.33	0.25	0.45	1.00	Ct
(0.15 - 0.74)	(0.10 - 0.62)	(0.22 - 0.92)	(0.52 - 1.92)	Suptavumab

Appendix table S13: league table of rate of ICU admission in fixed effects model

Matariannah	0.52	0.10	
Motavizumab	(0.24 - 1.12)	(0.01 - 0.85)	
0.47	Palivizumab	0.54	
(0.23 - 0.97)	Panvizumao	(0.27 - 1.07)	
0.23	0.50	DI I	
(0.09 - 0.59)	(0.26 - 0.95)	Placebo	

Appendix table S14: league table of rate of ICU admission in random effects model

Motavizumab	0.52	0.10	
iviotavizumao	(0.24 - 1.12)	(0.01 - 0.85)	
0.47	Palivizumab	0.54	
(0.23 - 0.97)	Falivizulilau	(0.27 - 1.07)	
0.23	0.50	Placebo	
(0.09 - 0.59)	(0.26 - 0.95)	r iaceuu	

Appendix table S15: league table of rate of mechanical ventilation use in fixed effects model

Matariannah	0.18	0.25	
Motavizumab	(0.04 - 0.81)	(0.02 - 2.76)	
0.23	Palivizumab	0.57	
(0.06 - 0.83)	Panvizumao	(0.24 - 1.38)	
0.14	0.62	Placebo	
(0.03 - 0.57)	(0.27 - 1.43)	Ріасево	

$\textbf{Appendix table S16: league table of rate of mechanical ventilation use in random \ effects \ model } \\$

Matariannah	0.18	0.25
Motavizumab	(0.04 - 0.81)	(0.02 - 2.76)
0.23	Palivizumab	0.57
(0.06 - 0.83)	Panvizumao	(0.24 - 1.38)
0.14	0.62	Dl l
(0.03 - 0.57)	(0.27 - 1.43)	Placebo

Appendix table S17: league table of drug-related adverse events in fixed effects model

M+P	0.76 (0.40 - 1.42)				
0.76 (0.40 - 1.42)	Motavizumab		0.99 (0.69 - 1.42)		
0.83	1.10	Nirsevimab		0.93	·
(0.30 - 2.32)	(0.49 - 2.47)			(0.51 - 1.68)	
0.75	0.99	0.90	Palivizumab	1.03	
(0.36 - 1.54)	(0.69 - 1.42)	(0.44 - 1.85)	T un vizumue	(0.68 - 1.56)	•
0.77	1.02	0.93	1.03	DI I	0.99
(0.34 - 1.77)	(0.59 - 1.76)	(0.51 - 1.68)	(0.68 - 1.56)	Placebo	(0.60 - 1.65)
0.77	1.01	0.92	1.02	0.99	Cuntarumah
(0.29 - 2.03)	(0.48 - 2.14)	(0.42 - 2.01)	(0.53 - 1.97)	(0.60 - 1.65)	Suptavumab

Appendix table S18: league table of drug-related adverse events in random effects model

M+P	0.76				
IVI+I	(0.40 - 1.42)	•	•	•	•
0.76	Motavizumab		0.99		
(0.40 - 1.42)	Wiotavizuiliao	•	(0.69 - 1.42)	•	•
0.83	1.10	Nirsevimab		0.93	
(0.30 - 2.32)	(0.49 - 2.47)	Niiseviiiao		(0.51 - 1.68)	•
0.75	0.99	0.90	Dallarian al	1.03	
(0.36 - 1.54)	(0.69 - 1.42)	(0.44 - 1.85)	Palivizumab	(0.68 - 1.56)	•
0.77	1.02	0.93	1.03	Placebo	0.99
(0.34 - 1.77)	(0.59 - 1.76)	(0.51 - 1.68)	(0.68 - 1.56)	Flacebo	(0.60 - 1.65)
0.77	1.01	0.92	1.02	0.99	Cuntayumah
(0.29 - 2.03)	(0.48 - 2.14)	(0.42 - 2.01)	(0.53 - 1.97)	(0.60 - 1.65)	Suptavumab

Appendix table S19: league table of rate of supplemental oxygen use in fixed effects model

Matariannah		0.64	0.12
Motavizumab		(0.39 - 1.06)	(0.07 - 0.19)
0.90	Nirsevimab		0.13
(0.26 - 3.04)	Nirsevimao		(0.04 - 0.39)
0.64	0.72	Palivizumab	
(0.39 - 1.06)	(0.19 - 2.68)	Panvizumao	٠
0.12	0.13	0.18	Dlacako
(0.07 - 0.19)	(0.04 - 0.39)	(0.09 - 0.37)	Placebo

Appendix table S20: league table of rate of supplemental oxygen use in random effects model

Motavizumab		0.64	0.12
Wiotavizumao	•	(0.39 - 1.06)	(0.07 - 0.19)
0.90	Nirsevimab		0.13
(0.26 - 3.04)	Nirsevimab	•	(0.04 - 0.39)
0.64	0.72	Palivizumab	
(0.39 - 1.06)	(0.19 - 2.68)	Panvizumao	·
0.12	0.13	0.18	Dl l
(0.07 - 0.19)	(0.04 - 0.39)	(0.09 - 0.37)	Placebo

Appendix table S21: cumulative ranking of interventions for different outcomes

Strategies were ranked according to P score, which is the mean extent of certainty that one intervention is better than another, averaged over all competing interventions.

Outcome	Rank	Intervention
Rate of RSV infection	1	Motavizumab
	2	Nirsevimab
	3	Palivizumab
	4	Placebo
	5	Suptavumab
All-cause mortality	1	Nirsevimab
	2	Palivizumab
	3	Motavizumab
	4	M+P
	5	Placebo
RSV-related hospitalization	1	Nirsevimab
	2	Motavizumab
	3	Palivizumab
	4	Suptavumab
	5	Placebo
Rate of supplemental oxygen use	1	Motavizumab
	2	Nirsevimab
	3	Palivizumab
	4	Placebo
Rate of mechanical ventilation use	1	Motavizumab
	2	Palivizumab
	3	Placebo
Rate of ICU admission	1	Motavizumab
	2	Palivizumab
	3	Placebo
Drug-related adverse events	1	M+P
	2	Nirsevimab
	3	Placebo
	4	Suptavumab
	5	Motavizumab
	6	Palivizumab

Appendix table S22: details of GRADE assessment in all-cause mortality

All-cause mortality						
Comparison	Direct odds ratio (95%	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence
Nirsevimab vs. Placebo	0.33 [0.05, 1.97]	High			0.33 [0.05, 1.97]	Moderate‡
Motavizumab vs. Placebo	1.00 [0.18, 5.48]	High	0.62 [0.22, 1.78]	High	0.71 [0.29, 1.74]	Moderate‡
Palivizumab vs. Placebo	0.70 [0.41, 1.19]	High	1.13 [0.16, 7.73]	High	0.72 [0.43, 1.21]	Moderate‡
Suptavumab vs. Placebo	1.37 [0.06, 33.61]	Moderate*			1.37 [0.06, 33.61]	Low§
Motavizumab vs. Palivizumab	0.89 [0.36, 2.20]	High	1.43 [0.24, 8.49]	High	0.98 [0.44, 2.20]	Moderate‡
M+P vs. Motavizumab	1.12 [0.10, 12.54]	Moderate†			1.12 [0.10, 12.54]	Low§
M+P vs. Nirsevimab			2.43 [0.11, 55.88]	Moderate†	2.43 [0.11, 55.88]	Low§
M+P vs. Palivizumab			1.10 [0.09, 14.04]	Moderate†	1.10 [0.09, 14.04]	Low§
M+P vs. Placebo			0.80 [0.06, 10.46]	Moderate†	0.80 [0.06, 10.46]	Low§
Motavizumab vs. Nirsevimab			2.16 [0.29, 16.03]	High	2.16 [0.29, 16.03]	Moderate‡
Nirsevimab vs. Palivizumab			0.45 [0.07, 2.93]	High	0.45 [0.07, 2.93]	Moderate‡
Suptavumab vs. M+P						
Suptavumab vs. Motavizumab						
Suptavumab vs. Nirsevimab						
Suptavumab vs. Palivizumab						

^{*}Downgraded 1 level due to risk of bias.

[†]Downgraded 1 level due to risk of bias.

[‡]Downgraded 1 level due to imprecision.

[§]Downgraded 2 level due to imprecision and risk of bias.

Appendix table S23: details of GRADE assessment in RSV-related hospitalization

RSV-related hospitalization						
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence
Nirsevimab vs. Placebo	0.25 [0.13, 0.47]	High			0.25 [0.13, 0.47]	High
Palivizumab vs. Placebo	0.45 [0.34, 0.60]	High			0.45 [0.34, 0.60]	High
Motavizumab vs. Palivizumab	0.73 [0.50, 1.08]	High			0.73 [0.50, 1.08]	Moderate†
Suptavumab vs. Placebo	1.00 [0.52, 1.92]	Moderate*			1.00 [0.52, 1.92]	Low‡
Motavizumab vs. Nirsevimab			1.34 [0.60, 3.01]	High	1.34 [0.60, 3.01]	Moderate†
Motavizumab vs. Placebo			0.33 [0.20, 0.53]	High	0.33 [0.20, 0.53]	High
Motavizumab vs. Suptavumab			0.33 [0.15, 0.74]	Moderate*	0.33 [0.15, 0.74]	Moderate*
Nirsevimab vs. Palivizumab			0.55 [0.27, 1.12]	High	0.55 [0.27, 1.12]	Moderate†
Nirsevimab vs. Suptavumab			0.25 [0.10, 0.62]	Moderate*	0.25 [0.10, 0.62]	Moderate*
Palivizumab vs. Suptavumab			0.45 [0.22, 0.92]	Moderate*	0.45 [0.22, 0.92]	Moderate*

^{*}Downgraded 1 level due to risk of bias.

[†]Downgraded 1 level due to imprecision.

[‡]Downgraded 2 level due to imprecision and risk of bias.

Appendix table S24: details of GRADE assessment in rate of RSV infection

Rate of RSV infection						
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence
Nirsevimab vs. Placebo	0.24 [0.16, 0.37]	High			0.24 [0.16, 0.37]	High
	1	1	T	T	Γ	, ,
Motavizumab vs. Placebo	0.17 [0.12, 0.23]	High			0.17 [0.12, 0.23]	Moderate‡
Palivizumab vs. Placebo	0.32 [0.22, 0.47]	Moderate*			0.32 [0.22, 0.47]	Moderate*
Suptavumab vs. Placebo	1.06 [0.73, 1.53]	Moderate*			1.06 [0.73, 1.53]	Low†
Motavizumab vs. Nirsevimab			0.68 [0.41, 1.14]	High	0.68 [0.41, 1.14]	Moderate‡
Motavizumab vs. Palivizumab			0.52 [0.32, 0.86]	Moderate*	0.52 [0.32, 0.86]	Moderate*
Motavizumab vs. Suptavumab			0.16 [0.10, 0.25]	Moderate*	0.16 [0.10, 0.25]	Moderate*
Nirsevimab vs. Palivizumab			0.77 [0.44, 1.35]	Moderate*	0.77 [0.44, 1.35]	Low†
Nirsevimab vs. Suptavumab			0.23 [0.13, 0.40]	Moderate*	0.23 [0.13, 0.40]	Moderate*
Palivizumab vs. Suptavumab			0.30 [0.18, 0.51]	Moderate*	0.30 [0.18, 0.51]	Moderate*

^{*}Downgraded 1 level due to risk of bias.

[†]Downgraded 2 level due to risk of bias and imprecision.

[‡]Downgraded 1 level due to imprecision.

Appendix table S25: details of GRADE assessment in drug-related adverse events

	Drug-related AE						
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence	
Nirsevimab vs. Placebo	0.93 [0.51, 1.68]	High			0.93 [0.51, 1.68]	Moderate†	
Palivizumab vs. Placebo	1.03 [0.68, 1.56]	High			1.03 [0.68, 1.56]	Moderate†	
Motavizumab vs. Palivizumab	0.99 [0.69, 1.42]	High			0.99 [0.69, 1.42]	Moderate†	
M+P vs. Motavizumab	0.76 [0.40, 1.42]	Moderate*			0.76 [0.40, 1.42]	Low‡	
Suptavumab vs. Placebo	1.01 [0.61, 1.68]	Moderate*			1.01 [0.61, 1.68]	Low‡	
M+P vs. Nirsevimab			0.83 [0.30, 2.32]	Moderate*	0.83 [0.30, 2.32]	Low‡	
M+P vs. Palivizumab			0.75 [0.36, 1.54]	Moderate*	0.75 [0.36, 1.54]	Low‡	
M+P vs. Placebo			0.77 [0.34, 1.77]	Moderate*	0.77 [0.34, 1.77]	Low‡	
M+P vs. Suptavumab			0.77 [0.29, 2.03]	Moderate*	0.77 [0.29, 2.03]	Low‡	
Motavizumab vs. Nirsevimab			1.10 [0.49, 2.47]	High	1.10 [0.49, 2.47]	Moderate†	
Motavizumab vs. Placebo			1.02 [0.59, 1.76]	High	1.02 [0.59, 1.76]	Moderate†	
Motavizumab vs. Suptavumab			1.01 [0.48, 2.14]	Moderate*	1.01 [0.48, 2.14]	Low‡	
Nirsevimab vs. Palivizumab			0.90 [0.44, 1.85]	High	0.90 [0.44, 1.85]	Moderate†	
Nirsevimab vs. Suptavumab			0.92 [0.42, 2.01]	Moderate*	0.92 [0.42, 2.01]	Low‡	
Palivizumab vs. Suptavumab			1.02 [0.53, 1.97]	Moderate*	1.02 [0.53, 1.97]	Low‡	

^{*}Downgraded 1 level due to risk of bias.

[†]Downgraded 1 level due to imprecision.

[‡]Downgraded 2 level due to imprecision and risk of bias.

Appendix table S26: details of GRADE assessment in supplemental oxygen use

Rate of supplemental oxygen use							
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence	
Nirsevimab vs. Placebo	0.13 [0.04, 0.39]	High			0.13 [0.04, 0.39]	Moderate*	
Motavizumab vs. Placebo	0.12 [0.07, 0.19]	High			0.12 [0.07, 0.19]	Moderate*	
Motavizumab vs. Palivizumab	0.64 [0.39, 1.06]	High			0.64 [0.39, 1.06]	Moderate*	
Motavizumab vs. Nirsevimab			0.90 [0.26, 3.04]	High	0.90 [0.26, 3.04]	Moderate*	
Nirsevimab vs. Palivizumab			0.72 [0.19, 2.68]	High	0.72 [0.19, 2.68]	Moderate*	
Palivizumab vs. Placebo			0.18 [0.09, 0.37]	High	0.18 [0.09, 0.37]	Moderate*	

^{*}Downgraded 1 level due to imprecision.

Appendix table S27: details of GRADE assessment in rate of mechanical ventilation use

Rate of MV use						
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence
Motavizumab vs. Placebo	0.25 [0.02, 2.76]	High	0.10 [0.02, 0.59]	High	0.14 [0.03, 0.57]	Moderate*
Palivizumab vs. Placebo	0.57 [0.24, 1.38]	High	1.39 [0.08, 23.67]	High	0.62 [0.27, 1.43]	Moderate*
Nirsevimab vs. Placebo	0.16 [0.01, 4.05]	High			0.16 [0.01, 4.05]	Moderate*
Motavizumab vs. Palivizumab	0.18 [0.04, 0.81]	High	0.44 [0.03, 5.61]	High	0.23 [0.06, 0.83]	Moderate*
Motavizumab vs. Nirsevimab						
Palivizumab vs. Nirsevimab						

^{*}Downgraded 1 level due to imprecision.

Appendix table S28: details of GRADE assessment in rate of ICU admission

Rate of ICU admission						
Comparison	Direct odds ratio (95% CI)	Certainty of evidence without imprecision	Indirect odds ratio (95% CI)	Certainty of evidence without imprecision	Network odds ratio (95% CI)	Certainty of evidence
Motavizumab vs. Placebo	0.10 [0.01, 0.85]	High	0.28 [0.10, 0.79]	High	0.23 [0.09, 0.59]	Moderate*
Palivizumab vs. Placebo	0.54 [0.27, 1.07]	High	0.19 [0.02, 1.87]	High	0.50 [0.26, 0.95]	Moderate*
Nirsevimab vs. Placebo	0.04 [0.00, 0.81]	High			0.04 [0.00, 0.81]	Moderate*
Motavizumab vs. Palivizumab	0.52 [0.24, 1.12]	High	0.18 [0.02, 1.76]	High	0.47 [0.23, 0.97]	Moderate*
Motavizumab vs. Nirsevimab						
Palivizumab vs. Nirsevimab						

^{*}Downgraded 1 level due to imprecision.

Appendix table S29: details of GRADE assessment in drug-related serious adverse events

Drug-related SAE					
Comparison	Direct odds ratio (95% CI)	Certainty of evidence			
Motavizumab vs. Placebo	8.56 [0.49, 148.58]	Moderate*			
Palivizumab vs. Placebo	0.14 [0.01, 2.80]	Moderate*			
Nirsevimab vs. Placebo					
Motavizumab vs. Palivizumab	0.82 [0.25, 2.71]	Moderate*			
M+P vs. Motavizumab	1.12 [0.10, 12.54]	Low†			

^{*}Downgraded 1 level due to imprecision.

[†]Downgraded 2 level due to imprecision and risk of bias.

${\bf Appendix\ table\ S30\text{-}S45\text{:}\ Bayesian\ league\ tables\ of\ outcomes\ in\ fixed\ and\ random\ models}$

Outcomes were reported as odds ratio (95% credible interval). All tables list the treatments in alphabetical order. The estimate is in the cell in common between the column-defining intervention and the row-defining intervention. The league table contains pairwise comparisons of the treatment in the row versus the treatment in the column in the lower triangle and column versus row in the upper triangle.

Appendix table S30: Bayesian league table of rate of RSV infection in random effects model

Motavizumab	1.45 (0.37, 5.65)	1.97 (0.58, 7.97)	6.02 (2.02, 17.99)	6.40 (1.37, 30.44)
0.69	N' ' 1	1.36	4.14	4.40
(0.18, 2.72)	Nirsevimab	(0.49, 4.48)	(1.83, 9.60)	(1.13, 17.82)
0.51	0.74	Palivizumab	3.05	3.26
(0.13, 1.73)	(0.22, 2.04)	Panvizuniao	(1.36, 5.94)	(0.81, 11.29)
0.17	0.24	0.33	Placebo	1.06
(0.06, 0.50)	(0.10, 0.55)	(0.17, 0.74)	Piaceoo	(0.36, 3.23)
0.16	0.23	0.31	0.94	Control
(0.03, 0.73)	(0.06, 0.88)	(0.09, 1.24)	(0.31, 2.79)	Suptavumab

Appendix table S31: Bayesian league table of rate of RSV infection in fixed effects model

Motavizumab	1.47	1.91	6.03	6.42
Motavizumab	(0.87, 2.45)	(1.16, 3.13)	(4.43, 8.31)	(3.97, 10.45)
0.68	Nirsevimab	1.30	4.11	4.37
(0.41, 1.15)	Niiseviinao	(0.74, 2.28)	(2.75, 6.22)	(2.55, 7.64)
0.53	0.77	Palivizumab	3.17	3.37
(0.32, 0.86)	(0.44, 1.35)	Panvizumao	(2.17, 4.65)	(2.00, 5.76)
0.17	0.24	0.32	Placebo	1.06
(0.12, 0.23)	(0.16, 0.36)	(0.21, 0.46)	Placedo	(0.74, 1.54)
0.16	0.23	0.30	0.94	Cuntayumah
(0.1, 0.25)	(0.13, 0.39)	(0.17, 0.50)	(0.65, 1.35)	Suptavumab

Appendix table S32: Bayesian league table of all-cause mortality in random effects model

M+P	0.73 (0.02, 9.32)	0.91 (0.02, 21.63)	0.72 (0.02, 10.7)	1.04 (0.03, 15.68)	113751.74 (0.19, 1764267809536012800)
1.38 (0.11, 43.94)	Motavizumab	1.28 (0.23, 8.13)	1 (0.44, 2.28)	1.45 (0.58, 3.55)	171012.94 (0.49, 2485624818560194560)
1.09	0.78		0.79	1.14	130929.84
(0.05, 49.59)	(0.12, 4.39)	Nirsevimab	(0.14, 3.69)	(0.22, 4.86)	(0.34, 1885003463665145600)
1.38	1	1.26	D 1' ' 1	1.44	169161.91
(0.09, 47.81)	(0.44, 2.26)	(0.27, 7.04)	Palivizumab	(0.86, 2.43)	(0.51, 2442958399732975616)
0.96	0.69	0.88	0.69	DI I	117377.89
(0.06, 33.48)	(0.28, 1.71)	(0.21, 4.53)	(0.41, 1.16)	Placebo	(0.36, 1628536804196702720)
0	0	0	0	0	Contonuel
(0, 5.4)	(0, 2.05)	(0, 2.94)	(0, 1.96)	(0, 2.77)	Suptavumab

Appendix table S33: Bayesian league table of all-cause mortality in fixed effects model

Man	0.73	0.91	0.72	1.04	113751.74
M+P	(0.02, 9.32)	(0.02, 21.63)	(0.02, 10.7)	(0.03, 15.68)	(0.19, 1764267809536012800)
1.38	Motavizumab	1.28	1	1.45	171012.94
(0.11, 43.94)	Wiotavizuiliab	(0.23, 8.13)	(0.44, 2.28)	(0.58, 3.55)	(0.49, 2485624818560194560)
1.09	0.78	Nirsevimab	0.79	1.14	130929.84
(0.05, 49.59)	(0.12, 4.39)	Nirsevilliao	(0.14, 3.69)	(0.22, 4.86)	(0.34, 1885003463665145600)
1.38	1	1.26	Palivizumab	1.44	169161.91
(0.09, 47.81)	(0.44, 2.26)	(0.27, 7.04)	Panvizumao	(0.86, 2.43)	(0.51, 2442958399732975616)
0.96	0.69	0.88	0.69	Placebo	117377.89
(0.06, 33.48)	(0.28, 1.71)	(0.21, 4.53)	(0.41, 1.16)	Placedo	(0.36, 1628536804196702720)
0	0	0	0	0	Suptavumab
(0, 5.4)	(0, 2.05)	(0, 2.94)	(0, 1.96)	(0, 2.77)	Supavulliab

Appendix table S34: Bayesian league table of RSV-related hospitalization in random effects model

Motavizumab	1.52	1.37	5.9	6.02
Motavizumab	(0.02, 260.25)	(0.04, 51.21)	(0.16, 472.6)	(0.04, 1972.77)
0.66	Nirsevimab	0.88	3.91	3.98
(0, 52.44)	Niiseviinao	(0.03, 14.59)	(0.3, 53.02)	(0.05, 344.37)
0.73	1.13	Palivizumab	4.43	4.44
(0.02, 25.9)	(0.07, 36.1)	Faiivizuiliao	(1.06, 35.88)	(0.11, 357.65)
0.17	0.26	0.23	Placebo	1.01
(0, 6.29)	(0.02, 3.38)	(0.03, 0.94)	Piacebo	(0.03, 38.5)
0.17	0.25	0.23	0.99	Cuntayumah
(0, 25.25)	(0, 20.55)	(0, 8.76)	(0.03, 36.09)	Suptavumab

Appendix table S35: Bayesian league table of RSV-related hospitalization in fixed effects model

M-ti	0.84	1.37	3.5	3.54
Motavizumab	(0.37, 1.87)	(0.93, 2.01)	(2.17, 5.65)	(1.59, 8.16)
1.19	Nirsevimab	1.62	4.15	4.22
(0.54, 2.73)	Niiseviinao	(0.81, 3.4)	(2.2, 8.21)	(1.69, 11.05)
0.73	0.62	D-li-i	2.56	2.59
(0.5, 1.07)	(0.29, 1.24)	Palivizumab	(1.94, 3.39)	(1.28, 5.43)
0.29	0.24	0.39	Placebo	1.01
(0.18, 0.46)	(0.12, 0.45)	(0.29, 0.52)	Piacebo	(0.53, 2.01)
0.28	0.24	0.39	0.99	Suptavumab
(0.12, 0.63)	(0.09, 0.59)	(0.18, 0.78)	(0.5, 1.88)	Suptavulliau

Appendix table S36: Bayesian league table of rate of supplemental oxygen use in random effects model

Motavizumab	1.04	1.55	8.84
Motavizumao	(0.02, 54.33)	(0.1, 24.05)	(0.57, 135.5)
0.96	Nirsevimab	1.5	8.43
(0.02, 52.12)	Niiseviinao	(0.01, 191.09)	(0.49, 154.15)
0.64	0.67	Palivizumab	5.68
(0.04, 9.81)	(0.01, 84.42)	Fanvizumao	(0.12, 270.02)
0.11	0.12	0.18	Placebo
(0.01, 1.75)	(0.01, 2.06)	(0, 8.5)	Piaceoo

Appendix table S37: Bayesian league table of rate of supplemental oxygen use in fixed effects model

W	1.06	1.56	8.79	
Motavizumab	(0.26, 3.45)	(0.95, 2.6)	(5.37, 15.11)	
0.94	Nirsevimab	1.48	8.27	
(0.29, 3.82)	Nirsevimab	(0.41, 6.49)	(2.91, 30.8)	
0.64	0.68	Delladaman	5.65	
(0.38, 1.05)	(0.15, 2.45)	Palivizumab	(2.77, 11.7)	
0.11	0.12	0.18	Dlasaka	
(0.07, 0.19)	(0.03, 0.34)	(0.09, 0.36)	Placebo	

Appendix table S38: Bayesian league table of rate of mechanical ventilation use in random effects model

Motavizumab	0 (0, 11.96)	5.03 (0.63, 45.73)	7.7 (0.74, 83.84)
24058.21	Nirsevimab	122529.85	183653.94
(0.08, 855629723170699904)	Nirsevimab	(0.48, 4252162126839230976)	(0.87, 5821885953627409408)
0.2	0	Palivizumah	1.54
(0.02, 1.59)	(0, 2.1)	Fanvizumao	(0.21, 10.2)
0.13	0	0.65	Placebo
(0.01, 1.35)	(0, 1.16)	(0.1, 4.82)	r iacebo

Appendix table S39: Bayesian league table of rate of mechanical ventilation use in fixed effects model

Matariannal	0	4.96	8.27
Motavizumab	(0, 7.71)	(1.52, 23.27)	(2.12, 43.62)
26691.14	Nirsevimab	138661.44	227408.63
(0.13, 56102833244432992)	Niiseviinao	(0.76, 309977006714859136)	(1.31, 518393465197570240)
0.2	0	Palivizumab	1.64
(0.04, 0.66)	(0, 1.32)	Panvizumab	(0.72, 3.96)
0.12	0	0.61	Placebo
(0.02, 0.47)	(0, 0.76)	(0.25, 1.4)	r iacebo

Appendix table S40: Bayesian league table of rate of ICU admission in random effects model

Matariannah	0	2.53	6.12
Motavizumab	(0, 0.35)	(0.17, 54.84)	(0.4, 191.16)
5847429934.38	Nirsevimab	15616450915.69	40371913834.37
(2.86, 1.673431187075e+26)	Niiseviiiao	(8.23, 4.51961657999075e+26)	(25.82, 1.03437981491577e+27)
0.4	0	D.F	2.39
(0.02, 5.99)	(0, 0.12)	Palivizumab	(0.16, 50.19)
0.16	0	0.42	Placebo
(0.01, 2.5)	(0, 0.04)	(0.02, 6.26)	

Appendix table S41: Bayesian league table of rate of ICU admission in fixed effects model

Matariannal	0	2.22	4.66	
Motavizumab	(0, 0.14)	(1.1, 4.81)	(1.92, 12.04)	
217989677350.61	490291654606.98		1025081497855.31	
(6.9, 1.01180718649146e+31)	Nirsevimab	(15.84, 2.24726925127156e+31)	(33.16, 4.47461804254501e+31)	
0.45	0	Palivizumab	2.08	
(0.21, 0.91)	(0, 0.06)	Panvizumab	(1.1, 4.17)	
0.21	0	0.48	Placebo	
(0.08, 0.52)	(0, 0.03)	(0.24, 0.91)	r iaceoo	

Appendix table S42: Bayesian league table of drug-related adverse events in random effects model

M. P.	1.32	1.34	1.29	1.25	1.27
M+P	(0.43, 3.99)	(0.23, 8.62)	(0.32, 4.76)	(0.24, 5.96)	(0.18, 8.34)
0.76	Motavizumab	1.02	0.98	0.95	0.96
(0.25, 2.32)	Motavizumab	(0.26, 4.49)	(0.43, 2.04)	(0.29, 2.9)	(0.19, 4.45)
0.75	0.98	Nirsevimab	0.96	0.93	0.95
(0.12, 4.3)	(0.22, 3.92)	Nirsevimao	(0.26, 2.93)	(0.37, 2.02)	(0.23, 3.38)
0.78	1.02	1.04	Palivizumab	0.97	0.99
(0.21, 3.17)	(0.49, 2.34)	(0.34, 3.82)	Panvizumao	(0.42, 2.32)	(0.26, 3.93)
0.8	1.06	1.07	1.03	Placebo	1.02
(0.17, 4.13)	(0.34, 3.48)	(0.49, 2.69)	(0.43, 2.4)	Flacebo	(0.35, 2.93)
0.79	1.04	1.05	1.01	0.99	Suptavumab
(0.12, 5.58)	(0.22, 5.15)	(0.3, 4.39)	(0.25, 3.91)	(0.34, 2.83)	Suptavulliao

Appendix table S43: Bayesian league table of drug-related adverse events in fixed effects model

	1.32	1.34	1.33	1.29	1.31
M+P	(0.69, 2.46)	(0.48, 3.75)	(0.64, 2.74)	(0.55, 2.96)	(0.49, 3.49)
0.76	Matariana	1.01	1.01	0.98	0.99
(0.41, 1.44)	Motavizumab	(0.46, 2.29)	(0.7, 1.45)	(0.56, 1.69)	(0.47, 2.12)
0.75	0.99	Nirsevimab	1	0.97	0.98
(0.27, 2.09)	(0.44, 2.18)	Nirsevimab	(0.48, 2.02)	(0.53, 1.71)	(0.45, 2.13)
0.75	0.99	1	Palivizumab	0.97	0.98
(0.36, 1.57)	(0.69, 1.42)	(0.49, 2.09)	Panvizumao	(0.64, 1.46)	(0.51, 1.92)
0.78	1.02	1.03	1.03	Placebo	1.01
(0.34, 1.8)	(0.59, 1.77)	(0.58, 1.9)	(0.68, 1.56)	Flacebo	(0.61, 1.72)
0.76	1.01	1.02	1.02	0.99	Cuntavumah
(0.29, 2.04)	(0.47, 2.13)	(0.47, 2.24)	(0.52, 1.95)	(0.58, 1.63)	Suptavumab

Appendix table S44: Bayesian league table of drug-related serious adverse events in random effects model

M.D.	0.71	20222.9	0.17	0.25
M+P	(0.01, 48.35)	(0, 1.84127748263721e+29)	(0, 26.53)	(0, 61.71)
1.4	31979.62		0.25	0.37
(0.02, 147.72)	Motavizumab	(0, 2.1964172568143e+29)	(0.01, 4.39)	(0.01, 12.1)
0	0	Nirsevimab	0	0
(0, 2985881300883712)	(0, 1697149564964730)	Niiseviinao	(0, 433416757509325)	(0, 511717295620109)
5.97	4.07	142821.12	D 11 1	1.41
(0.04, 2028)	(0.23, 132.29)	(0, 1.04766699009681e+30)	Palivizumab	(0.04, 84.76)
4.02	2.68	94516.74	0.71	Placebo
(0.02, 1803.64)	(0.08, 151.91)	(0, 5.53272420784994e+29)	(0.01, 24.09)	

Appendix table S45: Bayesian league table of drug-related serious adverse events in fixed effects model

M+P	0.74	14312.42	0.45	0.33
MI+P	(0.02, 9.58)	(0, 6.39254240399028e+28)	(0.01, 7.68)	(0.01, 6.43)
1.35	Motavizumab	21367.07	0.63	0.47
(0.1, 44.04)	(0, 8.86040823969649e+28)		(0.18, 1.96)	(0.09, 1.88)
0	0	NT: 1	0	0
(0, 1347470867106858)	(0, 784023877300891)	Nirsevimab	(0, 504596108636899)	(0, 346926025479572)
2.2	1.59	33999.92	Palivizumab	0.74
(0.13, 84.25)	(0.51, 5.41)	(0, 1.38689577917869e+29)	Faiivizuiliao	(0.13, 3.63)
3.03	2.12	47959.76	1.35	Placebo
(0.16, 134.87)	(0.53, 11.6)	(0, 1.86085058214622e+29)	(0.28, 7.75)	r iacebo

Appendix table S46: details of continuous outcomes


First author, year	Intervention	Comparison	Participants (I/C)	mean (I)	mean (C)					
Duration of MV use (total days/100 children)										
O'Brien KL, 2015	'Brien KL, 2015 Motavizumab Placebo 1417/710 0.21 1.83									
Carbonell-Estrany, 2010	Motavizumab	Palivizumab	3329/3306	0.5	3.8					
Feltes, 2003	Palivizumab	Placebo	639/648	6.5	54.7					
	Duration of RS	V-related hospital stay	(total days/100 children)							
O'Brien KL, 2015	Motavizumab	Placebo	1417/710	7.41	52.96					
Carbonell-Estrany, 2010	Motavizumab	Palivizumab	3329/3306	9.1	18.1					
Feltes, 2003	Palivizumab	Placebo	639/648	57.4	129					
Griffin MP, 2020	Nirsevimab	Placebo 969/484		5.37	28.93					
	Duration	of RSV ICU stay (total	days/100 children)							
O'Brien KL, 2015	Motavizumab	Placebo	1417/710	0.28	3.66					
Carbonell-Estrany, 2010	Motavizumab	Palivizumab	3329/3306	2	6.3					
Feltes, 2003	Palivizumab	Placebo	Placebo 639/648		71.2					
Duration of supplemental oxygen use										
O'Brien KL, 2015	Motavizumab	Placebo	1417/710	6.28	44.93					
Carbonell-Estrany, 2010	Motavizumab Palivizumab 3329/3306		3329/3306	4.1	9.5					
Feltes, 2003	Palivizumab	Placebo	639/648	27.9	101.5					

APPENDIX FIGURES

Appendix figure S1: risk of bias assessment




Appendix figure S1-1: risk of bias assessment for dichotomous outcome




Appendix figure S1-2: risk of bias assessment for continuous outcome

Appendix figure S2-S9: network plots


Network plot comparing mAbs in preventing RSV in children. The line width is proportional to the number of studies comparing each pair of interventions, and the size of each node is proportional to the number of participants (sample size).




Appendix figure S2: network plot of rate of RSV infection




Appendix figure S3: network plot of all-cause mortality




Appendix figure S4: network plot of RSV-related hospitalization




Appendix figure S5: network plot of supplemental oxygen use




Appendix figure S6: network plot of rate of mechanical ventilation use



Appendix figure S7: network plot of rate of ICU admission



Appendix figure S8: network plot of drug-related adverse events



Appendix figure S9: network plot of drug-related serious adverse events

Appendix figure S10-S15: forest plots of all-cause mortality in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (\mathbf{D}) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results (F) Overall

Appendix figure S10: results of motavizumab compared with placebo in all-cause mortality

	Nirsevi	mab	Place	bo		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
Domachowske, 2018	0	71	0	18		Not estimable		? ?
Griffin, 2020	2	968	3	479	62.4%	0.33 [0.05, 1.97]		$\Theta = \Theta = \Theta = \Theta$
Hammitt, 2022	3	987	0	491	37.6%	3.49 [0.18, 67.79]	-	
Total (95% CI)		2026		988	100.0%	0.80 [0.08, 7.97]		
Total events	5		3					
Heterogeneity: $Tau^2 = 1.37$; $Chi^2 = 1.88$, $df = 1$ (P = 0.17); $I^2 = 47\%$							0.001 0.1 1 10	1000
Test for overall effect: $Z = 0.19$ (P = 0.85)						F	0.001 0.1 1 10 [avours [experimental] Favours [contro	1000

- Risk of bias legend
 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
 (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S11: results of nirsevimab compared with placebo in all-cause mortality

	Palivizu	ımab	Place	bo		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
Feltes, 2003	21	639	27	648	81.6%	0.78 [0.44, 1.40]	-	999999
Subramanian, 1998	0	42	1	20	2.6%	0.15 [0.01, 3.93]	-	
The IMpact-RSV Study Group, 1998	4	1002	5	500	15.8%	0.40 [0.11, 1.48]		99999
Total (95% CI)		1683		1168	100.0%	0.67 [0.40, 1.14]	•	
Total events	25		33					
Heterogeneity: Tau ² = 0.00; Chi ² = 1	.67, df =	2 (P = 0)	0.43); I ² =	= 0%		±	005 01 10	200
Test for overall effect: Z = 1.48 (P =	0.14)						0.005 0.1 1 10 vours [experimental] Favours [contro	200 il]

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S12: results of palivizumab compared with placebo in all-cause mortality

	Suptavi	ımab	Place	bo		Odds Ratio			Odds Ratio			Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I	M-H	, Random, 9!	5% CI		ABCDEF
Simões, 2021	1	766	0	348		1.37 [0.06, 33.61]		1			? ?
							0.02	0.1	i	10	50	
							Favours	[experin	nental] Favou	urs [conti	rol]	

- Risk of bias legend (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S13: results of suptavumab compared with placebo in all-cause mortality

	Motaviz	umab	Palivizu	ımab	Odds Ratio	Odds	Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight M-H, Random, 95% (I M-H, Rando	om, 95% CI	ABCDEF
Feltes, 2011	9	618	10	612	0.89 [0.36, 2.2	` +		-
						0.05 0.2 1 Favours [experimental]	l 5 Favours [contro	20 bl]

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

- (E) Bias in selection of the reported results (F) Overall

Appendix figure S14: results of motavizumab compared with palivizumab in all-cause mortality


	M+	P	Motaviz	umab		Odds Ratio		O	dds Ratio)		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ra	andom, 9	5% CI		ABCDEF
Fernández, 2010	2	166	1	93		1.12 [0.10, 12.54]			1	-		? ?
							0.05	0.2	i	5	20	
						F	avours	experimen	tal] Favo	urs [cont	rol]	

- Risk of bias legend
 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S15: results of motavizumab in combination with palivizumab compared with motavizumab in all-cause

mortality

Appendix figure S16-S20: forest plots of drug-related adverse events in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S16: results of nirsevimab compared with placebo in drug-related adverse events

	Palivizu	ımab	Place	bo		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% CI	ABCDEF
Feltes, 2003	46	639	45	648	92.5%	1.04 [0.68, 1.59	1	
Subramanian, 1998	6	42	3	20	7.5%	0.94 [0.21, 4.24	T -	99999
Total (95% CI)		681		668	100.0%	1.03 [0.68, 1.56]	•	
Total events	52		48					
Heterogeneity: Tau ² =	= 0.00; Ch	$i^2 = 0.0$	01, df = 1	1 (P = 0)	$(0.90); I^2 =$	0%	0.2 0.5 1 2 5	
Test for overall effect	z = 0.15	(P = 0.	.88)				Favours [experimental] Favours [contro	1]

- Risk of bias legend
 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S17: results of palivizumab compared with placebo in drug-related adverse events

	Suptavu	ımab	Place	bo		Odds Ratio		Odd	ds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	М	-H, Rar	ndom, 95% CI	ABCDEF
Simões, 2021	51	766	23	348		1.01 [0.61, 1.68]	7	-		? ?
						Fa	2000	5 0.7 rimenta	1 1.5 2 al] Favours [control]	

- Risk of bias legend
 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to deviations from the interfede in (C) Bias due to missing data (D) Bias due to measurement of the outcome (E) Bias in selection of the reported results (F) Overall

Appendix figure S18: results of suptavumab compared with placebo in drug-related adverse events

	Motaviz	umab	Palivizu	ımab		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI	ABCDEF
Carbonell-Estrany, 2010	13	3315	10	3298	19.0%	1.29 [0.57, 2.96	5]	00000
Feltes, 2011	51	618	54	612	81.0%	0.93 [0.62, 1.39	oj —	
Total (95% CI)		3933		3910	100.0%	0.99 [0.69, 1.42		
Total events	64		64					
Heterogeneity: $Tau^2 = 0.0$	0; $Chi^2 = 0$	0.50, df	= 1 (P =	0.48); 1	$^{2} = 0\%$		0.5 0.7 1 1.5 2	- 2
Test for overall effect: Z =	0.06 (P =	0.96)					Favours [experimental] Favours [control]	

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S19: results of motavizumab compared with palivizumab in drug-related adverse events


	M+	P	Motaviz	umab		Odds Ratio		Odds	Ratio		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	lom, 95% CI		ABCDEF
Fernández, 2010	30	166	21	93	778-2	0.76 [0.40, 1.42]					? ?
							0.2	0.5	1 2	5	
							Favour	s [experimental]	Favours [control]		

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S20: results of motavizumab in combination with palivizumab compared with motavizumab in drug-related

adverse events

Appendix figure S21-S25: forest plots of drug-related serious adverse events in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S21: results of motavizumab compared with placebo in drug-related serious adverse events

	Nirsevi	mab	Place	bo		Odds Ratio		(Odds Ratio			Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, I	Random, 9	5% CI		ABCDEF
Griffin, 2020	0	968	0	479		Not estimable						
							0.01	0.1	i	10	100	
						1	Favours	[experime	ntal] Favoı	ırs [conti	rol]	

- Risk of bias legend

 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S22: results of nirsevimab compared with placebo in drug-related serious adverse events

	Palivizu	ımab	Place	bo		Odds Ratio		Oc	lds Ratio		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ra	andom, 95% CI		ABCDEF
Feltes, 2003	0	639	3	648		0.14 [0.01, 2.80]					00000
							0.002	0.1	1 10	500	
							Favoure le	vnerimen	tall Favours Ico	ntroll	

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results (F) Overall

Appendix figure S23: results of palivizumab compared with placebo in drug-related serious adverse events

	Motaviz	umab	Palivizu	ımab		Odds Ratio		(Odds Ratio	0		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H,	Random, 9	95% CI		ABCDEF
Feltes, 2011	5	618	6	612		0.82 [0.25, 2.71]	- 5		1		ă.	99999
							0.05	0.2	i	5	20	
							avours	[experime	ntal] Favo	ours [cont	trol]	

- Risk of bias legend (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S24: results of motavizumab compared with palivizumab in drug-related serious adverse events


	M+	P	Motaviz	umab		Odds Ratio		Oc	dds Ratio	0		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ra	andom, 9	95% CI		ABCDEF
Fernández, 2010	2	166	1	93		1.12 [0.10, 12.54]	r		1			? ?
						F	0.05 avours [e	0.2 xperiment	i tal] Favo	5 ours [co	20 ntrol]	

- (A) Bias from the randomization process generated
 (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S25: results of motavizumab in combination with palivizumab compared with motavizumab in drug-related

serious adverse events

Appendix figure S26-S29: forest plots of rate of RSV-related hospitalization in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S26: results of nirsevimab compared with placebo in RSV-related hospitalization

	Palivizu	ımab	Place	bo		Odds Ratio	Odds	Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Rand	om, 95% CI	ABCDEF
Blanken, 2013	2	214	11	215	9.5%	0.17 [0.04, 0.80]		
Feltes, 2003	34	639	63	648	40.1%	0.52 [0.34, 0.80]		
Subramanian, 1998	2	42	2	20	5.7%	0.45 [0.06, 3.45	i	_	
Tavsu, 2014	0	78	20	82	3.1%	0.02 [0.00, 0.33			?? + + ?
The IMpact-RSV Study Group, 1998	48	1002	53	500	41.5%	0.42 [0.28, 0.64	-		99999
Total (95% CI)		1975		1465	100.0%	0.39 [0.23, 0.65	•		
Total events	86		149				1998 I		
Heterogeneity: $Tau^2 = 0.12$; $Chi^2 = 7$.24, df =	4 (P = 0)).12); I ² =	= 45%			0.001 0.1	10 1000	
Test for overall effect: $Z = 3.62$ (P =	0.0003)						0.001 0.1 : Favours [experimental]	1 10 1000 Favours [control]	

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S27: results of palivizumab compared with placebo in RSV-related hospitalization

	Suptavi	ımab	Place	bo		Odds Ratio	Odds	Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Rand	om, 95% CI	ABCDEF
Simões, 2021	28	766	14	383		1.00 [0.52, 1.92]			? + + + ?
							0.5 0.7		
						F	avours [experimental]	Favours [control]	

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S28: results of suptavumab compared with placebo in RSV-related hospitalization

	Motaviz	umab	Palivizu	mab	Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
Carbonell-Estrany, 2010	46	3329	62	3306	0.73 [0.50, 1.08] Fa	0.5 0.7 1 1.5 2	-

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S29: results of motavizumab compared with palivizumab in RSV-related hospitalization

Appendix figure S30-S33: forest plots of rate of RSV infection in pairwise meta-analysis

	Motaviz	umab	Place	bo		Odds Ratio		Odds	s Rati	o			Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 9	5% C	CI .		ABCDEF
O'Brien, 2015	61	1417	151	710		0.17 [0.12, 0.23]	-				- 1		
						Fa	0.1 0.2 avours [expe	0.5 erimental]	i Fav	2 ours	5 [cont	10 rol]	

Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S30: results of motavizumab compared with placebo in RSV infection

	Nirsevi	mab	Place	bo		Odds Ratio	Odds R	atio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed,	, 95% CI	ABCDEF
Griffin, 2020	25	969	46	484	64.5%	0.25 [0.15, 0.42]			00000
Hammitt, 2022	12	994	25	496	35.5%	0.23 [0.11, 0.46]	-		
Total (95% CI)		1963		980	100.0%	0.24 [0.16, 0.37]	•		
Total events	37		71						
Heterogeneity: Chi ² =	0.04, df	= 1 (P =	= 0.84); I	$^{2} = 0\%$			0.05 0.2 1	5 20	- ,
Test for overall effect	Z = 6.80	(P < 0)	.00001)			F	avours [experimental] F		

- <u>Risk of bias legend</u>
 (A) Bias from the randomization process generated
 (B) Bias due to deviations from the intended intervention

- (C) Bias due to missing data
 (D) Bias due to measurement of the outcome
 (E) Bias in selection of the reported results
 (F) Overall

Appendix figure S31: results of nirsevimab compared with placebo in RSV infection

	Palivizu	ımab	Place	bo		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	ABCDEF
Blanken, 2013	10	214	30	215	29.4%	0.30 [0.14, 0.64]		
Subramanian, 1998	6	42	4	20	4.8%	0.67 [0.17, 2.69]	($\bullet \bullet \bullet \bullet \bullet$
Tavsu, 2014	40	156	88	164	65.8%	0.30 [0.19, 0.48]	-	?? ? • • ?
Total (95% CI)		412		399	100.0%	0.32 [0.22, 0.46]	•	
Total events	56		122				***	
Heterogeneity: Chi ² =	= 1.17, df	= 2 (P =	= 0.56); 1	$^{2} = 0\%$			005 00	30
Test for overall effect	z = 5.90	(P < 0.	.00001)			Fa	0.05 0.2 1 5 avours [experimental] Favours [co	20 ontrol]

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (**D**) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S32: results of palivizumab compared with placebo in RSV infection

	Suptavu	ımab	Place	bo		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	ABCDEF
Simões, 2021	101	766	48	383		1.06 [0.73, 1.53]		? + + + ?
							0.5 0.7 1 1.5 2	_
						F	avours [experimental] Favours [control]	

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S33: results of suptavumab compared with placebo in RSV infection

Appendix figure S34-S36: forest plots of rate of supplemental oxygen use in pairwise meta-analysis

	Motaviz	umab	Place	bo		Odds Ratio		Od	ds Ratio		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rai	ndom, 95% CI		ABCDEF
O'Brien, 2015	19	1417	75	710		0.12 [0.07, 0.19]	19	1		- 10	
							0.05	0.2	1 5	20	-
						F	avours [e	experimenta	al] Favours [con	trol]	

Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S34: results of motavizumab compared with placebo in supplemental oxygen use

	Nirsevi	mab	Place	bo		Odds Ratio		Ode	ds Ratio		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rai	ndom, 95% CI		ABCDEF
Griffin, 2020	4	968	15	479		0.13 [0.04, 0.39]					
							0.02	0.1	1 10	50	
							Favour	s [experimenta	al] Favours [control]		

- Risk of bias legend (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall


Appendix figure S35: results of nirsevimab compared with placebo in supplemental oxygen use

	Motaviz	umab	Palivizu	ımab		Odds Ratio		Odd	ls Rati	D	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Ran	dom,	95% CI	ABCDEF
Carbonell-Estrany, 2010	26	3329	40	3306		0.64 [0.39, 1.06]			+		
						-	0.2	0.5	i	2	5
							avours	[experimenta	ij ravo	ours (contro	1]

- (A) Bias from the randomization process generated
- (\mathbf{B}) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S36: results of motavizumab compared with palivizumab in supplemental oxygen use

Appendix figure S37-S40: forest plots of rate of mechanical ventilation use in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S37: results of motavizumab compared with placebo in mechanical ventilation use

	Nirsevi	mab	Place	bo		Odds Ratio		Od	ds Ratio		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rai	ndom, 95% CI		ABCDEF
Griffin, 2020	0	968	1	479	55-25	0.16 [0.01, 4.05]	_				00000
							0.002	0.1	1 10	500	
						F	avours [e	xperimenta	al] Favours [cont	rol]	

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S38: results of nirsevimab compared with placebo in mechanical ventilation use

	Palivizu	ımab	Place	bo		Odds Ratio			Od	ds Ra	tio			Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI			M-H, Ra	ndom	, 95% C	CI		ABCDEF
Feltes, 2003	8	639	14	648		0.57 [0.24, 1.38]	i .	-	-	-				00000
							0.1	0.2	0.5	i	2	5	10	
							Ганан	we fare		.II F-	I	control	1	

- Risk of bias legend
 (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S39: results of palivizumab compared with placebo in mechanical ventilation use

	Motaviz	umab	Palivizu	ımab		Odds Ratio			Odds Ratio	Ďi.		Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		М-Н,	Random, 9	5% CI		ABCDEF
Carbonell-Estrany, 2010	2	3329	11	3306		0.18 [0.04, 0.81]	8-				100	99999
						1	0.02 avours	0.1	i ental] Favo	10 urs (contro	50	


- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
 (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S40: results of motavizumab compared with palivizumab in mechanical ventilation use

Appendix figure S41-S44: forest plots of rate of ICU admission in pairwise meta-analysis



Risk of bias legend

- (A) Bias from the randomization process generated
- (B) Bias due to deviations from the intended intervention
- (C) Bias due to missing data
- (D) Bias due to measurement of the outcome
- (E) Bias in selection of the reported results
- (F) Overall

Appendix figure S41: results of motavizumab compared with placebo in ICU admission

	Nirsevi	mab	Placebo			Odds Ratio		Odds Ratio			Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rai	ABCDEF		
Griffin, 2020	0	968	5	479		0.04 [0.00, 0.81]			- .	34	00000
							0.002	0.1	1 10	500	
							Favours I	experiment	all Favours Contr	roll	

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S42: results of nirsevimab compared with placebo in ICU admission

	Palivizumab		Placebo		Odds Ratio			Odds Ratio					Risk of Bias	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI				CI		ABCDEF	
Feltes, 2003	13	639	24	648		0.54 [0.27, 1.07]	2	97 -		-	12	20	1933	00000
							0.1	0.2	0.5	1	2	5	10	
						F	avours	[expe	rimenta	al] Fa	vours	[contr	ol]	

- Risk of bias legend

 (A) Bias from the randomization process generated

 (B) Bias due to deviations from the intended intervention

 (C) Bias due to missing data

 (D) Bias due to measurement of the outcome

 (E) Bias in selection of the reported results

 (F) Overall

Appendix figure S43: results of palivizumab compared with placebo in ICU admission

	Motaviz	umab	Palivizumab		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight M-H, Random, 95% CI	M-H, Random, 95% CI	A B C D E F
Carbonell-Estrany, 2010	10	3329	19	3306	0.52 [0.24, 1.12]	0.1 0.2 0.5 1 2 5 10 avours [experimental] Favours [control]	

Risk of bias legend

(A) Bias from the randomization process generated


(B) Bias due to deviations from the intended intervention

(C) Bias due to missing data

(D) Bias due to measurement of the outcome (E) Bias in selection of the reported results (F) Overall

Appendix figure S44: results of motavizumab compared with palivizumab in ICU admission


Appendix figure S45: funnel plot of all-cause mortality




Appendix figure S39: funnel plot of all-cause mortality

Appendix figure S46-S59: node-split plots


The number of the direct evidence column is the P-value to test for differences between groups.




Appendix figure S46: node-split plot of all-cause mortality in fixed effects model



Appendix figure S47: node-split plot of all-cause mortality in random effects model



Appendix figure S48: node-split plot of drug-related adverse events in fixed effects model



Appendix figure S49: node-split plot of drug-related adverse events in random effects model

Comparison	Number of Studies	Direct Evidence	Fixed effect model OF	95%-CI
Motavizumab:Pa Direct estimate Indirect estimate Network estimate	livizumab 1	0.90	0.52 0.18 0.47	[0.02; 1.76]
Motavizumab:Pla Direct estimate Indirect estimate Network estimate	acebo 1	0.19	0.10 0.28 0.23	[0.10; 0.79]
Palivizumab:Plac Direct estimate Indirect estimate Network estimate	cebo 1	0.92	0.54 0.19 0.50	[0.02; 1.87]


Appendix figure S50: node-split plot of rate of ICU admission in fixed effects model

Comparison	Number of Studies	Direct Evidence	Random effects model OF	95%-CI
Motavizumab:Pal Direct estimate Indirect estimate Network estimate	ivizumab 1	0.90	0.55 0.18 0.4	3 [0.02; 1.76]
Motavizumab:Pla Direct estimate Indirect estimate Network estimate	cebo 1	0.19	0.10 0.20 0.21	3 [0.10; 0.79]
Palivizumab:Plac Direct estimate Indirect estimate Network estimate	ebo 1	0.92	0.5 0.1! 0.5 0.1 0.5	0.02; 1.87]


Appendix figure S51: node-split plot of rate of ICU admission in random effects model

Comparison	Number of Studies	Direct Evidence	Fixed effect model	OR	95%-CI
Motavizumab:Pali Direct estimate Indirect estimate Network estimate	ivizumab 1	0.74).18).44).23	[0.04; 0.81] [0.03; 5.61] [0.06; 0.83]
Motavizumab:Pla Direct estimate Indirect estimate Network estimate	cebo 1	0.34).25).10).14	[0.02; 2.76] [0.02; 0.59] [0.03; 0.57]
Palivizumab:Place Direct estimate Indirect estimate Network estimate	ebo 1	0.91	1	0.57 1.39 0.62	[0.24; 1.38] [0.08; 23.67] [0.27; 1.43]


Appendix figure S52: node-split plot of rate of mechanical ventilation use in fixed effects model




Appendix figure S53: node-split plot of rate of mechanical ventilation use in random effects model




Appendix figure S54: node-split plot of rate of RSV infection in fixed effects model




Appendix figure S55: node-split plot of rate of RSV infection in random effects model




Appendix figure S56: node-split plot of rate of supplemental oxygen use in fixed effects model



Appendix figure S57: node-split plot of rate of supplemental oxygen use in random effects model



Appendix figure S58: node-split plot of RSV-related hospitalization in fixed effects model



Appendix figure S59: node-split plot of RSV-related hospitalization in random effects model


Appendix figure S60-S66: contribute plots

The contribution matrix shows how much each direct treatment effect contributes to each treatment effect estimate from network meta-analysis. The rows represent network treatment effects and columns represent the contribution of direct treatment effects.


	Direct comparisons in the network								
			AvsB	BvsD	BvsE	CvsE	DvsE		
	Mixed esti	mates							
		AvsB	99.9						
tes		BvsD		66.3	16.9		16.9		
tima		BvsE		42.2	1506		42.2		
s es		CvsE				100.0			
Network meta-analysis estimates		DvsE	- 1800-5- 20-51 20-500	6.3	6:3		87.4		
meta-	Indirect est	timates							
work		AvsC	26.8	19.6	7.2	26.8	196		
Net E		AvsD	45.4	36.2	9.2		972		
		AvsE	36.6	26.7	9.9		26.7		
		BvsC		26.7	9.9	36.6	26.7		
		CvsD		3:3	3:3	48.4	45.1		
Entire	e network		20.6	23.9	8:3	20.6	26.7		
Inclu	ded studies		1	1	1	1	2		

Appendix figure S60: contribute plot of all-cause mortality A: M+P; B: Motavizumab; C: Nirsevimab; D: Palivizumab; E:

Placebo



Appendix figure S61: contribute plot of rate of RSV infection A: Motavizumab; B: Nirsevimab; C: Palivizumab; D: Placebo; E: Suptavumab




Appendix figure S62: contribute plot of RSV-related hospitalization A: Motavizumab; B: Nirsevimab; C: Palivizumab; D:

Placebo; E: Suptavumab

			Dire	ect comp	arisons in	the network
			,	AvsB	AvsC	BvsC
Network meta-analysis estimates	A	AvsB AvsC BvsC	(81.2 45.0 7.3 — — —	904 1000 733	9.4 45.0 85.4
Entire netv	vork		(44.8	921	46.1
Included s	tudies			1	1	1

Appendix figure S63: contribute plot of rate of ICU admission A: Motavizumab; B: Palivizumab; C: Placebo



Appendix figure S64: contribute plot of rate of supplemental oxygen use A: Motavizumab; B: Nirsevimab; C: Palivizumab;

D: Placebo

			Di	Direct comparisons in the network					
				AvsB	AvsC	BvsC			
Network meta-analysis estimates	Mixed estimates	AvsB AvsC BvsC		58.9 39.6 7.8	20.6 20.7 7.8	20.6 39.6 84.4			
Netwo	- — — - Indirect estimates								
Entire net	twork			37.1	172	45.8			
Included	studies			1	1	1			

Appendix figure S65: contribute plot of rate of mechanical ventilation use A: Motavizumab; B: Palivizumab; C: Placebo


		Direct comparisons in the network						
		AvsB	BvsD	CvsE	DvsE	EvsF		
	Mixed estimates							
	AvsB	100.0	1.					
	BvsD		100.0	1.				
	CvsE		·	100.0	1.			
ites	DvsE	*1		·	100.0	1		
	EvsF				·	100.0		
network meta-analysis estimates	Indirect estimates			3-85-85-				
<u> </u>	AvsC	25.0	25.0	25.0	25.0			
ta-a	AvsD	50.0	50.0					
E	AvsE	33.3	33.3	*	83.3			
VOL	AvsF	25.0	25.0		25.0	25.0		
Vetv	BvsC		33.3	33.3	33.3			
_	BvsE		50.0		50.0			
	BvsF		33.3	·	33.3	33.3		
	CvsD			50.0	50.0	÷		
	CvsF	*	•	50.0	0	50.0		
	DvsF	*1	•	·	50.0	50.0		
intire	e network	15.6	25.0	15.6	28.1	15.6		
nclu	ded studies	1	2	2	2	1		

Appendix figure S66: contribute plot of drug-related adverse events A: M+P; B: Motavizumab; C: Nirsevimab; D:


Palivizumab; E: Placebo; F: Suptavumab

Appendix figure S67-S68: subgroup analysis

(F) Overall



Appendix figure S67: subgroup analysis of rate of RSV infection




Appendix figure S68: subgroup analysis of RSV-related hospitalization


⁽D) Bias due to measurement of the outcome (E) Bias in selection of the reported results

⁽F) Overall


Appendix figure S69-S71: plots of meta-regression



Appendix figure S69: meta-regression of age in RSV-related hospitalization




Appendix figure S70: meta-regression of gender in RSV-related hospitalization



Appendix figure S71: meta-regression of publication year in RSV-related hospitalization

Appendix figure S72: Comparison of different monoclonal antibodies on efficacy and safety outcomes



^{*}The numbers in the circles (light gray) represent the baseline risk, the numbers in the boxes represent the absolute risk of the outcome after using the intervention. For example, the baseline risk of RSV infection was 170 per 1000 participants (light gray), after using nirsevimab, the absolute risk was reduced to 47 per 1000 participants (dark green), which indicates that nirsevimab was the best of the four drugs.

^{*}AE: adverse events.